3552-33-8

Basic information

• Product Name: 2,5-FURANDIONE,3-ETHYL-4-METHYL-
• Synonyms: 2,5-FURANDIONE,3-ETHYL-4-METHYL-;3-ethyl-4-methyl-furan-2,5-dione;3-Ethyl-4-methyl-2,5-furandione;2-Ethyl-3-MethylMaleic Anhydride;EthylMethyl Maleic Anhydride;EthylMethylMaleic Anhydride
• CAS NO: 3552-33-8
• Molecular Formula: C₇H₈O₃
• Molecular Weight: 140.14
• Product Categories: Intermediates & Fine Chemicals;Miscellaneous Reagents;Pharmaceuticals;Miscellaneous Reagents, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 3552-33-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 231.8°Cat760mmHg
• Flash Point: 101.6°C
• Appearance: /
• Density: 1.171g/cm³
• Vapor Pressure: 0.061mmHg at 25°C
• Refractive Index: 1.479
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: Chloroform (Sparingly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: 2,5-FURANDIONE,3-ETHYL-4-METHYL-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-FURANDIONE,3-ETHYL-4-METHYL-(3552-33-8)
• EPA Substance Registry System: 2,5-FURANDIONE,3-ETHYL-4-METHYL-(3552-33-8)

Safety Data

• Hazardous Substances Data: 3552-33-8(Hazardous Substances Data)

Usage

Uses

One of the bioactive ingredients present in essential oil of the leaves of Maytenus obtusifolia (Celastraceae), showed antimicrobial activity against 13 strains of bacteria, and fungus and yeast. The oil showed significant antimicrobial activity against Sthaphylococcus aureus (ATCC 6538), Escherichia coli (ATCC 18739), Listeria monocytogenes (ATCC 9610), Candida albicans (ATCC 13803), Candida tropicalis (LM 37), Candida guilliermondii (LM V70) and Aspergillus flavus (LM 247).

InChI:InChI=1/C7H8O3/c1-3-5-4(2)6(8)10-7(5)9/h3H2,1-2H3

Upstream product

• 917-64-6 methyl magnesium iodide 
• 98453-81-7 2-(bromomethyl)-3-methyl maleic anhydrate 
• 766-39-2 2,3-Dimethylmaleic anhydride 
• 75-16-1 methylmagnesium bromide 
• 1191077-89-0 1-{3-[(7-ethyl-8-methyl-6-oxo-3,4-dihydro-2H-pyrrolo[2,1-b][1,3]thiazin-6(8aH)-yl)sulfanyl]propyl}-3-ethyl-4-methyl-1H-pyrrole-2,5-dione 
• 616-02-4 citraconic acid anhydride 
• 114687-40-0 O-propionyl thiohydroxamate 
• 119558-81-5 5-allyl-2,2,5-trimethyl-1,3-dioxane-4,6-dione 
• 74-90-8 hydrogen cyanide 
• 607-97-6 ethyl 2-ethyl-3-oxobutanoate 
• 4433-85-6 2-ethyl-3-oxobutanoic acid 

Downstream Products

• 20189-42-8 3-ethyl-4-methyl-pyrrole-2,5-dione 
• 631-31-2 2-ethyl-2-methylsuccinic acid 
• 115087-28-0 N-(4-chloro-2-fluoro-5-isopropoxyphenyl)-2-ethyl-3-methyl maleic acid imide 
• 17851-27-3 1-ethyl-2,4,5-trimethylbenzene 

Relevant articles and documents

Synthesis of the disubstituted maleic anhydride frame using a novel tandem radical-polar reaction

An unreported 5-endo-trig atom-transfer radical cyclization of cyclic N-α-dichloroacyl-ketene-N,S-acetals, which evolves as a tandem radical-polar process, is described. The reaction, which is carried out in the presence of a Cu(I) complex catalyst (10 mol%) and an inorganic base (i.e., carbonate), can be exploited as the key step for a novel, short, and versatile synthesis of the 3,4-disubstituted maleic anhydride nucleus. Georg Thieme Verlag Stuttgart.

Preparation method of 2-methyl-3-ethyl maleic amide

The invention relates to a preparation method of 2-methyl-3-ethyl maleic amide. The method comprises the following steps: preparing dimethyl maleic anhydride; preparing 2-methyl-3-ethyl maleic anhydride; and preparing 2-methyl-3-ethyl maleic amide. A process route develops a synthetic method of a series of maleimide and maleic anhydride, and meanwhile, a flavoring application experiment is performed on the series of precursor-aroma compounds, thereby providing an important support for developing novel perfume materials.

Compounds with anti-cancer activity

Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.